Chemoprophylaxis may be a prevention strategy for the sexual transmission of human immunodeficiency virus (HIV). Evidence suggests that condom use has waned with the availability of antiretroviral medication, at least in some resource-rich settings. Barrier methods of HIV prevention have inherent problems, and the potential for failure. Microbicide research has focused primarily on male-to-female transmission. Analogous to post-exposure prophylaxis, HIV prevention may be achieved by pre-exposure prophylaxis in some settings. Research in this potential strategy may be rewarding.
Piot P, Bartos M, Ghys PD, et al.The global impact of HIV/AIDS. Nature2001;410(6831):968-973. Review.
2.
Pallela FJ Jr, Delaney KM, Moorman AC, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med1998; 338(13):853-860.
3.
Carr A, Samaras K, Thorisdottir A, et al.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet1999; 353(9170):2093-2099.
4.
Oxfam. Cut the cost. Accessed August 10, 2003, at http://www.oxfam.org.uk/cutthecost/
5.
Dehne KL, Pokrovskiy V, Kobyshcha Y, Schwartländer B. Update on the epidemics of HIV and other sexually transmitted infections in the newly independent states of the former Soviet Union. AIDS2000;14(Suppl 3):S75-S84. Review.
6.
Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med2001;7(9):1016-1020.
7.
Kilmarx PH, Supawitkul S, Wankrairoj M, Uthaivoravit W, et al.Explosive spread and effective control of human immunodeficiency virus in northernmost Thailand: The epidemic in Chiang Rai province, 1988-99. AIDS2000;14(17):2731-2740.
8.
Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: A systematic review and meta-analysis. AIDS2000; 14(15):2361-2370. Review.
9.
Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature2001; 410(6831):1002-1007. Review.
10.
Barouch DH, Kuntsman J, Kuroda MJ, et al.Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature2002; 415(6869):335-339.
11.
Jost S, Bernard MC, Kaiser L, Yerly S, et al.A patient with HIV-1 superinfection. N Engl J Med2002; 347(10):731-736.
12.
Wyler DJ. Malaria chemoprophylaxis for the traveller. N Engl J Med1993; 329(1):31-37. Review.
13.
Richens J, Imrie J, Copas A. Condoms and seat belts: The parallels and the lessons. Lancet2000; 355(9201):400-403.
14.
Connor E, Sperling RS, Gelber R, Kiselev P, et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med1994; 331(18):1173-1180.
15.
Hill R, Ryan J, Stone A, Fransen L. Vaginal microbicides for the prevention of HIV/AIDS: Assessment of the potential market. Int J Pharm2000; 14(5):271-278.
16.
Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, et al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med1997; 337(21):1485-1490.
17.
Tsai CC, Follis KE, Sabo A, Beck TW, et al.Prevention of SIV infection in macaques by ® -9-(2-phosphonylmethoxypropyl) adenine. Science1995; 270:1197-1199.
18.
Tsai CC, Emau P, Follis KE, Beck TW, et al.Effectiveness of postinoculation ® -9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol1998; 72(5):4265-4273.
19.
Van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, et al.9-[2-(Phosphonomethoxy)propyl] adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother1996; 40(11):2586-2591.
20.
Ruprecht RM, Mullaney S, Bernard LD, Gama Sosa MA, et al.Vaccination with a live retrovirus: The nature of the protective immune response. Proc Natl Acad Sci USA1990; 87(14):5558-5562.
21.
Otten RA, Smith DK, Adams DR, Pullium JK, et al.Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol2000; 74(20):9771-9775.
22.
Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS1998; 12(9):1067-1078.
23.
Jackson JB, Barnett S, Apuzzo L, et al.Nevirapine prophylaxis for prevention of sexual/blood transmission in HIV uninfected subjects. XIV International AIDS Conference. July 7-12, 2002. Barcelona, Spain. (Abstract: MoOrD1105).
24.
Saag MS, Hahn BH, Gibbons J, Li Y, et al.Extensive variation of human immunodeficiency virus type-1 in vivo. Nature1988; 334(6181):440-444.
25.
Youle M, Wainberg MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?AIDS2003; 17(6):937-938.
26.
Bill & Melinda Gates Foundation. Family Health International receives grant to evaluate once-daily antiretroviral as a potential method of HIV prevention. Accessed August 10, 2003, at http://www.gatesfoundation.org/GlobalHealth/HIVAIDSTB/HIVAIDS/Announcements/Announce-021028.htm
